Symposium 19: Secretagogues: sulfonylureas and incretins
| Autor: | Víctor Commendatore |
|---|---|
| Jazyk: | Spanish; Castilian |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Revista de la Sociedad Argentina de Diabetes, Vol 54, Iss 3Sup, Pp 77-77 (2020) |
| Druh dokumentu: | article |
| ISSN: | 0325-5247 2346-9420 |
| DOI: | 10.47196/diab.v54i3Sup.353 |
| Popis: | Symposium 19: Drug Treatment: What's New? Secretagogues: sulfonylureas and incretins Both SUs and iDPP4 have earned a spot within current Diabetes (DM) therapy. Regarding SUs, we refer to glimepiride, gliclazide and glipizide. Since glimepiride has lately been advised against, we will leave its qualities aside in neonatal DM treatment and MODY 3 to focus on its place within the schemes of T2D approach, answering the fundamental questions: Are they still present in treatment guidelines? SAD 2016, WHO 2018, IDF 2019, NICE 2019, ALAD 2019, MSN 2020 and AACE-ACE 2020, among others, consider them an option to be used in monotherapy (if there is contraindication or metformin tolerance) or as a second or third association to T2D treatment . |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|